Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
Status:
Terminated
Trial end date:
2018-10-11
Target enrollment:
Participant gender:
Summary
TERAVECT is a phase III randomized study of patients with digestive neuroendocrine tumors
after complete surgical resection of liver metastases treated with In111-Pentetreotide-based
adjuvant radiotherapy.
In this study, targeted radionuclide therapy is used at an earlier stage of the disease.The
objective is to target residual tumor cells and/or micrometastases which escaped surgical
resection. Given the poor prognosis associated with recurrence, this treatment should prevent
relapse.
Phase:
Phase 3
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)